1. Scrip
  2. >>Market Snapshot

Hereditary Angioedema Market Snapshot: Room For Pills And Injections As Prophylaxis Makes Gains

 
• By Ayisha Sharma

While many HAE patients converted from injectable prophylaxis to BioCryst’s oral Orladeyo last year, physicians said a promising injectable candidate from Ionis could benefit from varied patient preference.  

Dozens of colourful balloons are released into the sky at the International Rare Disease Day in Sofia, Bulgaria
Hereditary Angioedema Is a Rare Disease That Causes Extreme Swelling • Source: Alamy

The hereditary angioedema (HAE) market was shaken up last year by the launch of BioCryst Pharmaceuticals, Inc.’s plasma kallikrein inhibitor Orladeyo (berotralstat), the first oral prophylactic. Patients were previously limited to prophylactics with a more burdensome route of administration, such as Takeda Pharmaceutical Co. Ltd.’s subcutaneous plasma kallikrein inhibitor Takhzyro (lanadelumab).

HAE involves repeat episodes of swelling in the face, airway, limbs and intestines, causing vomiting, severe pain and even death from asphyxiation

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Snapshot

IgAN Market Snapshot: Growing Market, But Patient Segmentation Still A Question

 
• By Alaric DeArment

IgA nephropathy has gone from having zero to three approved treatments in just a few years, with over half a dozen more in late-stage development. But there are still many unknowns.

Atopic Dermatitis Market Snapshot: A Crowded Field With Room To Grow

 
• By Jessica Merrill

Topical, oral and biologic drugs have made a difference for patients with atopic dermatitis, but full control remains elusive for many, with the heterogeneous condition, leaving open a door for new medications.

Myeloma Market Snapshot: New Drug Classes On The Way, But Cost Could Be A Problem

 
• By Alaric DeArment

More BCMA-directed therapies are in development, as well as ones targeting GPRC5D and FcRH5, along with CELMoDs. The question is how to bring those into therapy and pay for them.

Myeloma Market Snapshot: Backlogs Dog BCMA CAR-Ts As Treatment Paradigm Evolves

 
• By Alaric DeArment

KOLs told Scrip about how they are incorporating new immunotherapies into treatment and combining existing agents, but some new drug classes have struggled to take root.

More from Scrip

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

AbbVie On MFN: ‘We Have To Take It Seriously’

 
• By Jessica Merrill

AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.

Industry Leaders Grapple With Trump’s MFN Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on what Trump’s executive order on drug pricing could mean for US and European drug prices.